Clinical studies have found that a lower expression of ZHX2 and a higher KDM2A expression were associated with a shorter survival time, which was linked to the transcriptionally repressing KDM2A by ZHX2 in HCC. The gene discussed is ZHX2; the disease is hepatocellular carcinoma.